SCHEMBL29614895

SCHEMBL29614895

O=C(Nc1ccc2oc(-c3cccnc3)nc2c1)[C@H]1C[C@H]1c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.63
KDM4E B2RXH2 11/20 0.63
HPGD P15428 8/20 0.63
HSD17B10 Q99714 7/20 0.63
POLB P06746 6/20 0.63
USP2 O75604 2/20 0.63
ESR1 P03372 1/20 0.63
NPSR1 Q6W5P4 3/20 0.62
MAPT P10636 9/20 0.61
TP53 P04637 2/20 0.61
RAB9A P51151 6/20 0.61
NPC1 O15118 5/20 0.61
L3MBTL1 Q9Y468 2/20 0.59
PTK2B Q14289 1/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
TSHR P16473 2/20 0.58
GLA P06280 1/20 0.57
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19307174 1.00 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL24449110 1.00 ALDH1A1 (0.63) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL29000625 0.81 KDM4E (0.77) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL19307177 0.81 ALDH1A1 (0.74) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL2248127 0.80 KDM4E (0.89) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL2628677 0.80 KDM4E (0.59) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL2245746 0.78 MAPT (0.83) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL29681121 0.78 KDM4E (0.60) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL17544110 0.78 KDM4E (0.60) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL2245449 0.77 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES CORNELL UNIVERSITY 2022-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160705-A1 METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES PTGES, PTGS1, PTGES2 ALDH1A1 901/4885KDM4E 3937/4885HPGD 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.